| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/12/2005 | EP1495322A2 Heteroclitic analogs and related methods |
| 01/12/2005 | EP1495141A2 Hiv therapeutic |
| 01/12/2005 | EP1495130A1 Use of biomolecular targets in the treatment and visualization of brain tumors |
| 01/12/2005 | EP1495123A1 Erbb3 based methods and compositions for treating neoplasms |
| 01/12/2005 | EP1495121A2 Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
| 01/12/2005 | EP1495120A2 Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
| 01/12/2005 | EP1495117A2 Human deubiquitinating protease gene on chromosome 7 and its murine ortholog |
| 01/12/2005 | EP1495053A2 Angiopoietin-2 specific binding agents |
| 01/12/2005 | EP1495042A1 Blanched polyamine steroid derivatives |
| 01/12/2005 | EP1495034A2 Mimics of acyl coenzyme-a comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses |
| 01/12/2005 | EP1495031A1 Labeled oxazinocarbazoles as diagnostic agents |
| 01/12/2005 | EP1495030A1 Non-steroidal progesterone receptor modulators |
| 01/12/2005 | EP1495026A1 Methods and compositions comprising nitric oxide donors and opioid analgesics |
| 01/12/2005 | EP1495024A1 Dipyridodiazepinones as reverse transcriptase inhibitors |
| 01/12/2005 | EP1495023A1 Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same |
| 01/12/2005 | EP1495022A1 Diazabicyclo alkane derivatives with nk1 antagonistic activity |
| 01/12/2005 | EP1495021A2 Antiinfectve compounds, process for their preparation and pharmaceutical compositions containing them |
| 01/12/2005 | EP1495020A1 N-(morpholin-2yl) methyl acetamide derivatives as ccr-3 antagonists useful in the treatment of inflammatory diseases |
| 01/12/2005 | EP1495019A1 Novel glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof |
| 01/12/2005 | EP1495018A1 Tricyclic thrombin receptor antagonists |
| 01/12/2005 | EP1495017A2 Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators |
| 01/12/2005 | EP1495016A2 Heterocyclic compounds and their use as modulators of p38 map kinase |
| 01/12/2005 | EP1495014A2 Novel flavanoids and chalcones as chemotherapeutic, chemopreventive, and antiangiogenic agents |
| 01/12/2005 | EP1495009A2 Cyanamides useful as reversible inhibitors of cysteine proteases |
| 01/12/2005 | EP1495006A1 Inhibitors of glycinamide ribonucleotide transformylase |
| 01/12/2005 | EP1495005A1 Pyrazole compounds as anti-inflammatory and analgesic agents |
| 01/12/2005 | EP1495004A2 Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor ligands |
| 01/12/2005 | EP1495003A1 Fredericamycin derivatives |
| 01/12/2005 | EP1495002A1 Benzamide derivatives useful as histone deacetylase inhibitors |
| 01/12/2005 | EP1495000A1 Alpha, omega-dicarboximide derivatives as useful uro-selective a1a adrenoceptor blockers |
| 01/12/2005 | EP1494999A1 Occlusive composition comprising a poly(2-cyanoacrylate) monomer |
| 01/12/2005 | EP1494998A2 Multiple-component solid phases containing at least one active pharmaceutical ingredient |
| 01/12/2005 | EP1494997A1 Substituted aryl amides |
| 01/12/2005 | EP1494993A2 Novel curcumin analogues and uses thereof |
| 01/12/2005 | EP1494992A2 Carbocyclic and oxacarbocyclic fumaric acid oligomers |
| 01/12/2005 | EP1494989A2 Compounds that modulate ppar activity and methods for their preparation |
| 01/12/2005 | EP1494749A2 Process for preparation of pharmaceutical composition containing antiretroviral protease inhibitor with improved bioavailability |
| 01/12/2005 | EP1494730A1 Composition for hard tissue augmentation |
| 01/12/2005 | EP1494722A1 Treatment methods for eotaxin mediated inflammatory conditions |
| 01/12/2005 | EP1494719A1 Injectable veterinary composition for small animals |
| 01/12/2005 | EP1494718A1 Combination of an agent that attenuates topoisomerase i activity and an agent that inhibits heat shock protein 90 for use in chemotherapy |
| 01/12/2005 | EP1494705A1 A composition and method for killing of tumours |
| 01/12/2005 | EP1494700A2 Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents |
| 01/12/2005 | EP1494698A2 Compositions and methods for treating and preventing necrosis |
| 01/12/2005 | EP1494692A1 Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis |
| 01/12/2005 | EP1494691A2 Treatment of diseases involving defective gap junctional communication |
| 01/12/2005 | EP1494690A2 Cochleates made with purified soy phosphatidylserine |
| 01/12/2005 | EP1494687A2 Immunomodulatory polymeric antigens for treating inflammatory pathogies |
| 01/12/2005 | EP1494686A2 Oral rehydration composition |
| 01/12/2005 | EP1494685A1 Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside |
| 01/12/2005 | EP1494684A2 USE OF dsRNAs IN STRATEGIC THERAPEUTIC INTERVENTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY |
| 01/12/2005 | EP1494683A1 Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
| 01/12/2005 | EP1494682A2 Polyphosphonate derivatives for toothpaste compositions |
| 01/12/2005 | EP1494681A2 Methods of simultaneously treating ocular rosacea and acne rosacea |
| 01/12/2005 | EP1494680A1 Use of carbon-2-modified-vitamin d analogs to induce the formation of new bone |
| 01/12/2005 | EP1494679A1 Step-down estrogen therapy |
| 01/12/2005 | EP1494678A1 Method of hormonal therapy |
| 01/12/2005 | EP1494677A1 Use of methylene blue and related compounds to prevent or reverse an exaggerated hemodynamic reaction |
| 01/12/2005 | EP1494676A1 Fused quinoxaline derivatives as inhibitors of akt activity |
| 01/12/2005 | EP1494674A1 Carboximide derivatives as useful uro-selective alpha-1a adrenoceptor blockers |
| 01/12/2005 | EP1494672A1 Aminocarbonyl substituted pyridines, pyridazines, pyrimidines, pyrazines and triazines having antiangiogenic activity |
| 01/12/2005 | EP1494671A1 1-(4-piperidinyl)benzimidazolones as histamine h3 antagonists |
| 01/12/2005 | EP1494670A1 Medicine for treating cancer |
| 01/12/2005 | EP1494669A1 Medicament for preventing and/or treating chronic rejection |
| 01/12/2005 | EP1494668A2 Use of benzimidazole analogs in the treatment of cell proliferation |
| 01/12/2005 | EP1494667A1 Imidazole compounds as anti-inflammatory and analgesic agents |
| 01/12/2005 | EP1494666A1 Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group (cox-2 inhibitor), a polyethylene glycol and a free-radical scavenging antioxidant |
| 01/12/2005 | EP1494665A1 Use of statins and other immunomodulatory agents in the treatment of autoimmune disease |
| 01/12/2005 | EP1494664A2 Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease |
| 01/12/2005 | EP1494663A1 Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss |
| 01/12/2005 | EP1494662A1 Tnp-470 polymer conjugates and use thereof |
| 01/12/2005 | EP1494661A1 Ptx3 gene expression suppressing method |
| 01/12/2005 | EP1494659A1 Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amide and lactic acid or a lactic acid salt |
| 01/12/2005 | EP1494658A1 Natural phenolic products and derivatives thereof for protection against neurodegenerative diseases |
| 01/12/2005 | EP1494657A2 Removable anchored lung volume reduction devices and methods |
| 01/12/2005 | EP1494656A1 Analgesic oral composition with controlled release of an opioid |
| 01/12/2005 | EP1494654A1 Palatable chewable tablet |
| 01/12/2005 | EP1494653A1 Sustained release pharmaceutical prepartations and methods for producing the same |
| 01/12/2005 | EP1494650A1 Pharmaceutical formulation comprising melatonin |
| 01/12/2005 | EP1494649A1 Nanoparticulate megestrol formulations |
| 01/12/2005 | EP1494648A1 Powder formulations suitable for inhalation |
| 01/12/2005 | EP1494645A2 Method of treating mucus hypersecretion |
| 01/12/2005 | EP1494644A1 Dry powder compositions |
| 01/12/2005 | EP1494634A1 Controlled delivery patch of active ingredient |
| 01/12/2005 | EP1494630A2 Bioadhesive drug delivery system |
| 01/12/2005 | EP1494629A2 Condom |
| 01/12/2005 | EP1494572A2 Controlled laser treatment for non-invasive tissue alteration, treatment and diagnostics with minimal collateral damage |
| 01/12/2005 | EP1494543A1 Dietary methods for canine performance enhancement |
| 01/12/2005 | EP1494536A1 Oil body associated protein compositions and methods of use thereof for reducing the risk of cardiovascular disease |
| 01/12/2005 | EP1494535A2 Compositions and minimally invasive methods for treating incomplete tissue repair |
| 01/12/2005 | EP1494533A2 Farnesoid x-activated receptor agonists |
| 01/12/2005 | EP1494530A2 Combination therapy using trefoil peptides |
| 01/12/2005 | EP1463515A4 Isoflavone composition for oral delivery |
| 01/12/2005 | EP1459760A9 Immunopotentiating inosine monophosphate 5'-nucleotidase resistant derivatives and uses thereof |
| 01/12/2005 | EP1443970A4 Promoters exhibiting endothelial cell specificity and methods of using same |
| 01/12/2005 | EP1434773A4 Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| 01/12/2005 | EP1414500A4 Akt and regulation of ra synovial fibroblast apoptosis |
| 01/12/2005 | EP1414435B1 Crystalline composition containing escitalopram |
| 01/12/2005 | EP1381605B1 Mercaptoacetylamide derivatives, a process for their preparation and their use |
| 01/12/2005 | EP1365781A4 Acrochordon alleviation |